A Multi-Model Approach to Nucleic Acid-Based Drug Development
- 1 January 2004
- journal article
- Published by Springer Nature in BioDrugs
- Vol. 18 (1) , 37-50
Abstract
With the advent of functional genomics and the shift of interest towards sequence-based therapeutics, the past decades have witnessed intense research efforts on nucleic acid-mediated gene regulation technologies. Today, RNA interference is emerging as a groundbreaking discovery, holding promise for development of genetic modulators of unprecedented potency. Twenty-five years after the discovery of antisense RNA and ribozymes, gene control therapeutics are still facing developmental difficulties, with only one US FDA-approved antisense drug currently available in the clinic. Limited predictability of target site selection models is recognized as one major stumbling block that is shared by all of the so-called complementary technologies, slowing the progress towards a commercial product. Currently employed in vitro systems for target site selection include RNAse H-based mapping, antisense oligonucleotide microarrays, and functional screening approaches using libraries of catalysts with randomized target-binding arms to identify optimal ribozyme/DNAzyme cleavage sites. Individually, each strategy has its drawbacks from a drug development perspective. Utilization of message-modulating sequences as therapeutic agents requires that their action on a given target transcript meets criteria of potency and selectivity in the natural physiological environment. In addition to sequence-dependent characteristics, other factors will influence annealing reactions and duplex stability, as well as nucleic acid-mediated catalysis. Parallel consideration of physiological selection systems thus appears essential for screening for nucleic acid compounds proposed for therapeutic applications. Cellular message-targeting studies face issues relating to efficient nucleic acid delivery and appropriate analysis of response. For reliability and simplicity, prokaryotic systems can provide a rapid and cost-effective means of studying message targeting under pseudo-cellular conditions, but such approaches also have limitations. To streamline nucleic acid drug discovery, we propose a multi-model strategy integrating high-throughputadapted bacterial screening, followed by reporter-based and/or natural cellular models and potentially also in vitro assays for characterization of the most promising candidate sequences, before final in vivo testing.Keywords
This publication has 202 references indexed in Scilit:
- A question of formNature, 2003
- RNA interferenceNature, 2002
- In Situ Demonstration of Inhibitory Effects of Hammerhead Ribozymes That Are Targeted to the Hepatitis Bx Sequence in Cultured CellsBiochemical and Biophysical Research Communications, 2000
- RNA Structure Comes of AgeCell, 1997
- Characterization and divalent metal-ion dependence of in vitro selected deoxyribozymes which cleave DNA/RNA chimeric oligonucleotidesJournal of Molecular Biology, 1997
- A ribozyme specifically suppresses transformation and tumorigenicity of Ha-ras-oncogene-transformed NIH/3T3 cell linesJournal of Cancer Research and Clinical Oncology, 1997
- Functional Characterization of Ribozymes Expressed Using U1 and T7 Vectors for the Intracellular Cleavage of ANF mRNABiochemistry, 1994
- Translation inhibition by an mRNA coding region secondary structure is determined by its proximity to the AUG initiation codonJournal of Molecular Biology, 1992
- Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and seraLife Sciences, 1991
- Can ribozymes be used to regulate procaryote gene expression?Biochemical and Biophysical Research Communications, 1989